A CD31-derived peptide prevents angiotensin II-induced atherosclerosis progression and aneurysm formation.

ABSTRACT:

Aims

The loss of the inhibitory receptor CD31 on peripheral T lymphocytes is associated with the incidence of atherosclerotic complications such as abdominal aortic aneurysms (AAA) in patients and plaque thrombosis in mice. However, we have recently discovered that a small fragment of extracellular CD31 remains expressed on the surface of the apparently 'CD31-negative' T-cells and that it is possible to restore the CD31-mediated T-cell inhibition in vivo by using a synthetic CD31-derived peptide. Here, we wanted to evaluate the therapeutic potential of the peptide in an experimental model of accelerated atherosclerosis and AAA formation.

Methods and results

The effect of the murine CD31-derived peptide (aa 551-574, 1.5 mg/kg/day, sc) was evaluated on the extent of atheroscle

SUBMITTER: Fornasa G 

PROVIDER: S-EPMC3680385 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature